Cochrane Abstracts
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rifaximin for Prevention and Treatment of Hepatic Encephalopathy in People With Cirrhosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440512/all/Rifaximin_for_prevention_and_treatment_of_hepatic_encephalopathy_in_people_with_cirrhosis.
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440512/all/Rifaximin_for_prevention_and_treatment_of_hepatic_encephalopathy_in_people_with_cirrhosis. Accessed March 26, 2025.
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440512/all/Rifaximin_for_prevention_and_treatment_of_hepatic_encephalopathy_in_people_with_cirrhosis
Rifaximin for Prevention and Treatment of Hepatic Encephalopathy in People With Cirrhosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440512/all/Rifaximin_for_prevention_and_treatment_of_hepatic_encephalopathy_in_people_with_cirrhosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
ID - 440512
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440512/all/Rifaximin_for_prevention_and_treatment_of_hepatic_encephalopathy_in_people_with_cirrhosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
